ESMO 2025

Details

21 October 2025

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics proffered paper session. Dr. Karolien Goffin discussed the previously presented trials by Drs. Kim Chi and Jeremie Calais:

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Irene Burger discussing optimized use of radioligand therapy in mCRPC. Dr. Burger started her presentation by emphasizing that there are many ways to improve outcomes in mCRPC with radioligand therapy (both ¹⁷⁷Lu-PSMA-617 and radium-223), but the ultimate aim is to improve outcomes and quality of life. For her presentation, Dr. Burger focused on five ways to optimize use of radioligand therapy.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Deborah Mukherji discussing optimized use of endocrine therapies and chemotherapies in mCRPC. Are we optimizing therapy for men with metastatic hormone sensitive prostate cancer (mHSPC)? Unfortunately, we are not, according to Dr. Mukherji. In a 2025 study from Rivas et al.¹ assessing health records, insurance claims, and cancer registries from eight European and North American databases, 69,680 mHSPC patients were identified, of whom 71% presented with synchronous mHSPC. Patients aged 70–79 years were most often treated with ADT monotherapy or ADT + androgen receptor pathway inhibitors, whereas those aged 60–69 years more frequently received ADT + chemotherapy or ADT + androgen receptor pathway inhibitors + chemotherapy. From 2016 through 2020, the adoption of androgen receptor pathway inhibitors-based combinations rose steadily, use of ADT + chemotherapy declined, and ADT monotherapy remained stable:

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted therapies in mCRPC. Dr. Omlin notes that the treatment landscape for advanced prostate cancer is vast, however his talk will specifically focus on ADT + checkpoint inhibition, ADT + targeted therapy, and sipuleucel-T:

Details

20 October 2025

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17^th and 21^st, 2025 was host to a renal and urothelial carcinoma proffered paper session. Dr. Lisa Pickering discussed the prior three abstract presentations:

Details

20 October 2025

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17^th and 21^st, 2025 was host to a radioligand therapeutics proffered paper session. Dr. Kim Chi presented the Canadian Cancer Trials Group (CCTG) Study PR.21, a randomized phase II study of ¹⁷⁷Lu-PSMA-617 versus docetaxel in mCRPC patients with PSMA-positive disease.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic testing in advanced prostate cancer. Dr. Paller started her presentation by defining germline versus somatic mutations:

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Johann S. De Bono discussing emerging new therapeutic strategies for advanced prostate cancer. Dr. De Bono started his presentation by noting that there are several adaptations to androgen receptor blockade, which include:

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Vincent Massard discussing the final analysis of patients treated with ¹⁷⁷Lu-PSMA-617 in an early access program in metastatic castration-resistant prostate cancer (mCRPC) in France. ¹⁷⁷Lu-PSMA-617 is a radiopharmaceutical with binding affinity to PSMA, expressed in 90% of mCRPC patients. The VISION trial showed that ¹⁷⁷Lu-PSMA-617 added to best standard of care prolonged imaging-based progression-free and overall survival in patients with PSMA-positive mCRPC.¹ Subsequently, the French Health Authorities granted early access for ¹⁷⁷Lu-PSMA-617 in this indication since December 2021 (which ended on April 29, 2025). This study assessed descriptive analyses comparing the characteristics, safety, and efficacy of ¹⁷⁷Lu-PSMA-617 in patients treated in France as part of the Early Access Program, with comparisons stratified by year of patient inclusion in the program.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a kidney cancer session and a presentation by Dr. Camillo Guglielmo Porta discussing the final analysis of lenvatinib + pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) with or without bone metastases in the CLEAR trial.¹ Bone metastases occur in approximately a third of patients with advanced RCC and are associated with a worse prognosis. RCC may induce immune cells to release factors that stimulate osteoclast formation, such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), which can lead to enhanced resorption. Specifically, alterations of the FGF/FGF receptor (FGFR) axis is associated with the development of bone metastases in several cancer types, including renal cancer.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Martin Boegemann, MD, discussing estimation of median overall survival to inform the ESMO-MCBS scores in non-metastatic castration-resistant prostate cancer (nmCRPC) using the ARAMIS study.¹ Assessing the clinical benefit of anticancer treatments is essential for guiding therapeutic decisions. As such, the ESMO-MCBS evaluates clinical benefit by assigning scores based on predefined criteria, with overall survival as a key factor. Overall survival is a relevant measure for patients and healthcare professionals that can be used to guide treatment decisions. In clinical trials where overall survival is not achieved, validated extrapolation can be used to calculate an estimated median overall survival.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Guillaume Grisay discussing EORTC GUCG 2418 STARBUST and strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies. The standard treatment for patients with muscle invasive bladder cancer consists of neoadjuvant systemic therapy followed by radical cystectomy or trimodal therapy. Currently, patients are not routinely reassessed after neoadjuvant systemic therapy and proceed directly to local treatment, leading to a missed opportunity for patients with complete or near complete response to benefit from bladder sparing strategies. On the other hand, for the non-responders, it is a missed opportunity to early systemic escalation. Unfortunately, several studies have shown an insufficient concordance between the clinical and pathological staging of muscle invasive bladder cancer, unraveling the inadequacy of the current methods for clinical stating post-neoadjuvant chemotherapy.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Guillaume Grisay discussing EORTC GUCG 2238 de-escalate, a pragmatic trial to revisit intermittent ADT in metastatic hormone-naïve prostate cancer in the era of new androgen receptor pathway inhibitors. The development of androgen receptor pathway inhibitors – abiraterone acetate, apalutamide, darolutamide, and enzalutamide – has profoundly reshaped the management of metastatic hormone-naïve prostate cancer (mHNPC). Seven trials have demonstrated that combining these drugs with ADT reduces the risk of death by 20 to 40%, delays the need for further treatment and improves health related quality of life. However, these trials are subject to two critical limitations: treatment duration and patient selection. Treatment typically continues until biochemical, radiological, or clinical progression occurs, sometimes many years after initiation, potentially exposing patients to chronic side effects that impact their quality of life. Furthermore, registration trials often include patient populations that are not representative of the general population. Several sub-analyses of these registration trials have shown that patients achieving a PSA level of ≤0.2 ng/ml have prolonged overall survival. In this study, the hypothesis was that patients reaching a PSA of ≤ 0.2 ng/ml might benefit from treatment interruption without compromising overall survival.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a biomarker-based personalization in metastatic prostate cancer session and a presentation by Dr. Ana Aparicio discussing aggressive variant prostate cancer. Dr. Aparicio started her presentation by highlighting the treatment landscape of metastatic prostate cancer based on approved and what are likely to be approved regimens:

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a testis cancer session and a presentation by Dr. Axel Heidenreich discussing the final results of the COTRIMS (COlogne Trial of Retroperitoneal Lymphadectomy in Metastastic Seminoma) trial. Radiation or chemotherapy represent the standard treatment in clinical stage IIA/B seminoma. Despite high cure rates, both modalities are associated with significant long-term toxicities. The COTRIMS trial evaluated the oncological and functional efficacy of primary retroperitoneal lymphadenectomy (RPLND) without adjuvant chemotherapy in CS IIA/B seminomas.¹

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Petros Grivas discussing INTerpath-011, a phase 2 study of intismeran autogene (V940/mRNA-4157) + BCG versus BCG alone for high-risk non muscle invasive bladder cancer. TURBT followed by intravesical BCG is the standard of care for patients with treatment-naive high-risk non muscle invasive bladder cancer.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Philippe Barthelemy discussing retreatment with ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) patients treated under the French early access program.

Details

20 October 2025

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17^th and 21^st was host to the Poster presentation session. Kim J. Van der Velden presented the poster Treatment intensification in the metastatic castration-sensitive prostate cancer (mCSPC) landscape: real-world evidence from 4,559 patients in the CAPRI-3 registry.

Details

20 October 2025

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17^th and 21^st was host to the Poster presentation session. Dr. J. Connor Wells presented the poster Durability of Complete Response (CR) to First Line (1L) in metastatic renal cell carcinoma (mRCC) in the Real World.

Details

20 October 2025

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Lucia Fratino discussing drug–drug interactions in older patients treated with abiraterone or enzalutamide for advanced prostate cancer. Older patients with metastatic castration-resistant prostate cancer (mCRPC) are frequently prescribed abiraterone or enzalutamide as first-line androgen receptor pathway inhibitors. Polypharmacy is common in this population, raising the risk of drug–drug interactions, which may compromise treatment adherence and patient safety. The MeetURO ADHERE study, a prospective Italian observational study, investigated adherence to androgen receptor pathway inhibitors in patients aged over 70 years, identifying concomitant medication use as a key factor influencing adherence.